Global Antisense and RNAi Therapeutics Market Research Report 2024(Status and Outlook)
Report Overview:
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".
The Global Antisense and RNAi Therapeutics Market Size was estimated at USD 1001.96 million in 2023 and is projected to reach USD 1289.90 million by 2029, exhibiting a CAGR of 4.30% during the forecast period.
This report provides a deep insight into the global Antisense and RNAi Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Antisense and RNAi Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Antisense and RNAi Therapeutics market in any manner.
Global Antisense and RNAi Therapeutics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc.
Market Segmentation (by Type)
RNA Interference
SiRNA
MiRNA
Antisense RNA
Market Segmentation (by Application)
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antisense and RNAi Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".
The Global Antisense and RNAi Therapeutics Market Size was estimated at USD 1001.96 million in 2023 and is projected to reach USD 1289.90 million by 2029, exhibiting a CAGR of 4.30% during the forecast period.
This report provides a deep insight into the global Antisense and RNAi Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Antisense and RNAi Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Antisense and RNAi Therapeutics market in any manner.
Global Antisense and RNAi Therapeutics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc.
Market Segmentation (by Type)
RNA Interference
SiRNA
MiRNA
Antisense RNA
Market Segmentation (by Application)
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Antisense and RNAi Therapeutics Market
- Overview of the regional outlook of the Antisense and RNAi Therapeutics Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antisense and RNAi Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Antisense and RNAi Therapeutics
1.2 Key Market Segments
1.2.1 Antisense and RNAi Therapeutics Segment by Type
1.2.2 Antisense and RNAi Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTISENSE AND RNAI THERAPEUTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Antisense and RNAi Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Antisense and RNAi Therapeutics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTISENSE AND RNAI THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Antisense and RNAi Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Antisense and RNAi Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Antisense and RNAi Therapeutics Sales Sites, Area Served, Product Type
3.6 Antisense and RNAi Therapeutics Market Competitive Situation and Trends
3.6.1 Antisense and RNAi Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Antisense and RNAi Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ANTISENSE AND RNAI THERAPEUTICS INDUSTRY CHAIN ANALYSIS
4.1 Antisense and RNAi Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTISENSE AND RNAI THERAPEUTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ANTISENSE AND RNAI THERAPEUTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antisense and RNAi Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Antisense and RNAi Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Antisense and RNAi Therapeutics Price by Type (2019-2024)
7 ANTISENSE AND RNAI THERAPEUTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antisense and RNAi Therapeutics Market Sales by Application (2019-2024)
7.3 Global Antisense and RNAi Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
8 ANTISENSE AND RNAI THERAPEUTICS MARKET SEGMENTATION BY REGION
8.1 Global Antisense and RNAi Therapeutics Sales by Region
8.1.1 Global Antisense and RNAi Therapeutics Sales by Region
8.1.2 Global Antisense and RNAi Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Antisense and RNAi Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Antisense and RNAi Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Antisense and RNAi Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Antisense and RNAi Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Antisense and RNAi Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Tekmira Pharmaceuticals
9.1.1 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
9.1.2 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
9.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
9.1.4 Tekmira Pharmaceuticals Business Overview
9.1.5 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
9.1.6 Tekmira Pharmaceuticals Recent Developments
9.2 Arbutus Biopharma
9.2.1 Arbutus Biopharma Antisense and RNAi Therapeutics Basic Information
9.2.2 Arbutus Biopharma Antisense and RNAi Therapeutics Product Overview
9.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Product Market Performance
9.2.4 Arbutus Biopharma Business Overview
9.2.5 Arbutus Biopharma Antisense and RNAi Therapeutics SWOT Analysis
9.2.6 Arbutus Biopharma Recent Developments
9.3 Alnylam Pharmaceuticals
9.3.1 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
9.3.2 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
9.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
9.3.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
9.3.5 Alnylam Pharmaceuticals Business Overview
9.3.6 Alnylam Pharmaceuticals Recent Developments
9.4 Antisense Therapeutics
9.4.1 Antisense Therapeutics Antisense and RNAi Therapeutics Basic Information
9.4.2 Antisense Therapeutics Antisense and RNAi Therapeutics Product Overview
9.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Product Market Performance
9.4.4 Antisense Therapeutics Business Overview
9.4.5 Antisense Therapeutics Recent Developments
9.5 Silence Therapeutics
9.5.1 Silence Therapeutics Antisense and RNAi Therapeutics Basic Information
9.5.2 Silence Therapeutics Antisense and RNAi Therapeutics Product Overview
9.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Product Market Performance
9.5.4 Silence Therapeutics Business Overview
9.5.5 Silence Therapeutics Recent Developments
9.6 Isis Pharmaceuticals
9.6.1 Isis Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
9.6.2 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
9.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
9.6.4 Isis Pharmaceuticals Business Overview
9.6.5 Isis Pharmaceuticals Recent Developments
9.7 Sirnaomics
9.7.1 Sirnaomics Antisense and RNAi Therapeutics Basic Information
9.7.2 Sirnaomics Antisense and RNAi Therapeutics Product Overview
9.7.3 Sirnaomics Antisense and RNAi Therapeutics Product Market Performance
9.7.4 Sirnaomics Business Overview
9.7.5 Sirnaomics Recent Developments
9.8 Santaris
9.8.1 Santaris Antisense and RNAi Therapeutics Basic Information
9.8.2 Santaris Antisense and RNAi Therapeutics Product Overview
9.8.3 Santaris Antisense and RNAi Therapeutics Product Market Performance
9.8.4 Santaris Business Overview
9.8.5 Santaris Recent Developments
9.9 Roche
9.9.1 Roche Antisense and RNAi Therapeutics Basic Information
9.9.2 Roche Antisense and RNAi Therapeutics Product Overview
9.9.3 Roche Antisense and RNAi Therapeutics Product Market Performance
9.9.4 Roche Business Overview
9.9.5 Roche Recent Developments
10 ANTISENSE AND RNAI THERAPEUTICS MARKET FORECAST BY REGION
10.1 Global Antisense and RNAi Therapeutics Market Size Forecast
10.2 Global Antisense and RNAi Therapeutics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Antisense and RNAi Therapeutics Market Size Forecast by Country
10.2.3 Asia Pacific Antisense and RNAi Therapeutics Market Size Forecast by Region
10.2.4 South America Antisense and RNAi Therapeutics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Antisense and RNAi Therapeutics by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Antisense and RNAi Therapeutics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Antisense and RNAi Therapeutics by Type (2025-2030)
11.1.2 Global Antisense and RNAi Therapeutics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Antisense and RNAi Therapeutics by Type (2025-2030)
11.2 Global Antisense and RNAi Therapeutics Market Forecast by Application (2025-2030)
11.2.1 Global Antisense and RNAi Therapeutics Sales (Kilotons) Forecast by Application
11.2.2 Global Antisense and RNAi Therapeutics Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Antisense and RNAi Therapeutics
1.2 Key Market Segments
1.2.1 Antisense and RNAi Therapeutics Segment by Type
1.2.2 Antisense and RNAi Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTISENSE AND RNAI THERAPEUTICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Antisense and RNAi Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Antisense and RNAi Therapeutics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTISENSE AND RNAI THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Antisense and RNAi Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Antisense and RNAi Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Antisense and RNAi Therapeutics Sales Sites, Area Served, Product Type
3.6 Antisense and RNAi Therapeutics Market Competitive Situation and Trends
3.6.1 Antisense and RNAi Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Antisense and RNAi Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ANTISENSE AND RNAI THERAPEUTICS INDUSTRY CHAIN ANALYSIS
4.1 Antisense and RNAi Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTISENSE AND RNAI THERAPEUTICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ANTISENSE AND RNAI THERAPEUTICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antisense and RNAi Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Antisense and RNAi Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Antisense and RNAi Therapeutics Price by Type (2019-2024)
7 ANTISENSE AND RNAI THERAPEUTICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antisense and RNAi Therapeutics Market Sales by Application (2019-2024)
7.3 Global Antisense and RNAi Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
8 ANTISENSE AND RNAI THERAPEUTICS MARKET SEGMENTATION BY REGION
8.1 Global Antisense and RNAi Therapeutics Sales by Region
8.1.1 Global Antisense and RNAi Therapeutics Sales by Region
8.1.2 Global Antisense and RNAi Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Antisense and RNAi Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Antisense and RNAi Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Antisense and RNAi Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Antisense and RNAi Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Antisense and RNAi Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Tekmira Pharmaceuticals
9.1.1 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
9.1.2 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
9.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
9.1.4 Tekmira Pharmaceuticals Business Overview
9.1.5 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
9.1.6 Tekmira Pharmaceuticals Recent Developments
9.2 Arbutus Biopharma
9.2.1 Arbutus Biopharma Antisense and RNAi Therapeutics Basic Information
9.2.2 Arbutus Biopharma Antisense and RNAi Therapeutics Product Overview
9.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Product Market Performance
9.2.4 Arbutus Biopharma Business Overview
9.2.5 Arbutus Biopharma Antisense and RNAi Therapeutics SWOT Analysis
9.2.6 Arbutus Biopharma Recent Developments
9.3 Alnylam Pharmaceuticals
9.3.1 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
9.3.2 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
9.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
9.3.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
9.3.5 Alnylam Pharmaceuticals Business Overview
9.3.6 Alnylam Pharmaceuticals Recent Developments
9.4 Antisense Therapeutics
9.4.1 Antisense Therapeutics Antisense and RNAi Therapeutics Basic Information
9.4.2 Antisense Therapeutics Antisense and RNAi Therapeutics Product Overview
9.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Product Market Performance
9.4.4 Antisense Therapeutics Business Overview
9.4.5 Antisense Therapeutics Recent Developments
9.5 Silence Therapeutics
9.5.1 Silence Therapeutics Antisense and RNAi Therapeutics Basic Information
9.5.2 Silence Therapeutics Antisense and RNAi Therapeutics Product Overview
9.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Product Market Performance
9.5.4 Silence Therapeutics Business Overview
9.5.5 Silence Therapeutics Recent Developments
9.6 Isis Pharmaceuticals
9.6.1 Isis Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
9.6.2 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
9.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Market Performance
9.6.4 Isis Pharmaceuticals Business Overview
9.6.5 Isis Pharmaceuticals Recent Developments
9.7 Sirnaomics
9.7.1 Sirnaomics Antisense and RNAi Therapeutics Basic Information
9.7.2 Sirnaomics Antisense and RNAi Therapeutics Product Overview
9.7.3 Sirnaomics Antisense and RNAi Therapeutics Product Market Performance
9.7.4 Sirnaomics Business Overview
9.7.5 Sirnaomics Recent Developments
9.8 Santaris
9.8.1 Santaris Antisense and RNAi Therapeutics Basic Information
9.8.2 Santaris Antisense and RNAi Therapeutics Product Overview
9.8.3 Santaris Antisense and RNAi Therapeutics Product Market Performance
9.8.4 Santaris Business Overview
9.8.5 Santaris Recent Developments
9.9 Roche
9.9.1 Roche Antisense and RNAi Therapeutics Basic Information
9.9.2 Roche Antisense and RNAi Therapeutics Product Overview
9.9.3 Roche Antisense and RNAi Therapeutics Product Market Performance
9.9.4 Roche Business Overview
9.9.5 Roche Recent Developments
10 ANTISENSE AND RNAI THERAPEUTICS MARKET FORECAST BY REGION
10.1 Global Antisense and RNAi Therapeutics Market Size Forecast
10.2 Global Antisense and RNAi Therapeutics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Antisense and RNAi Therapeutics Market Size Forecast by Country
10.2.3 Asia Pacific Antisense and RNAi Therapeutics Market Size Forecast by Region
10.2.4 South America Antisense and RNAi Therapeutics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Antisense and RNAi Therapeutics by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Antisense and RNAi Therapeutics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Antisense and RNAi Therapeutics by Type (2025-2030)
11.1.2 Global Antisense and RNAi Therapeutics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Antisense and RNAi Therapeutics by Type (2025-2030)
11.2 Global Antisense and RNAi Therapeutics Market Forecast by Application (2025-2030)
11.2.1 Global Antisense and RNAi Therapeutics Sales (Kilotons) Forecast by Application
11.2.2 Global Antisense and RNAi Therapeutics Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Antisense and RNAi Therapeutics Market Size Comparison by Region (M USD)
Table 5. Global Antisense and RNAi Therapeutics Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Antisense and RNAi Therapeutics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Antisense and RNAi Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Antisense and RNAi Therapeutics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2022)
Table 10. Global Market Antisense and RNAi Therapeutics Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Antisense and RNAi Therapeutics Sales Sites and Area Served
Table 12. Manufacturers Antisense and RNAi Therapeutics Product Type
Table 13. Global Antisense and RNAi Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Antisense and RNAi Therapeutics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Antisense and RNAi Therapeutics Market Challenges
Table 22. Global Antisense and RNAi Therapeutics Sales by Type (Kilotons)
Table 23. Global Antisense and RNAi Therapeutics Market Size by Type (M USD)
Table 24. Global Antisense and RNAi Therapeutics Sales (Kilotons) by Type (2019-2024)
Table 25. Global Antisense and RNAi Therapeutics Sales Market Share by Type (2019-2024)
Table 26. Global Antisense and RNAi Therapeutics Market Size (M USD) by Type (2019-2024)
Table 27. Global Antisense and RNAi Therapeutics Market Size Share by Type (2019-2024)
Table 28. Global Antisense and RNAi Therapeutics Price (USD/Ton) by Type (2019-2024)
Table 29. Global Antisense and RNAi Therapeutics Sales (Kilotons) by Application
Table 30. Global Antisense and RNAi Therapeutics Market Size by Application
Table 31. Global Antisense and RNAi Therapeutics Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Antisense and RNAi Therapeutics Sales Market Share by Application (2019-2024)
Table 33. Global Antisense and RNAi Therapeutics Sales by Application (2019-2024) & (M USD)
Table 34. Global Antisense and RNAi Therapeutics Market Share by Application (2019-2024)
Table 35. Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
Table 36. Global Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Antisense and RNAi Therapeutics Sales Market Share by Region (2019-2024)
Table 38. North America Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 43. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 44. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 45. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Tekmira Pharmaceuticals Business Overview
Table 47. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 48. Tekmira Pharmaceuticals Recent Developments
Table 49. Arbutus Biopharma Antisense and RNAi Therapeutics Basic Information
Table 50. Arbutus Biopharma Antisense and RNAi Therapeutics Product Overview
Table 51. Arbutus Biopharma Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Arbutus Biopharma Business Overview
Table 53. Arbutus Biopharma Antisense and RNAi Therapeutics SWOT Analysis
Table 54. Arbutus Biopharma Recent Developments
Table 55. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 56. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 57. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 59. Alnylam Pharmaceuticals Business Overview
Table 60. Alnylam Pharmaceuticals Recent Developments
Table 61. Antisense Therapeutics Antisense and RNAi Therapeutics Basic Information
Table 62. Antisense Therapeutics Antisense and RNAi Therapeutics Product Overview
Table 63. Antisense Therapeutics Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Antisense Therapeutics Business Overview
Table 65. Antisense Therapeutics Recent Developments
Table 66. Silence Therapeutics Antisense and RNAi Therapeutics Basic Information
Table 67. Silence Therapeutics Antisense and RNAi Therapeutics Product Overview
Table 68. Silence Therapeutics Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Silence Therapeutics Business Overview
Table 70. Silence Therapeutics Recent Developments
Table 71. Isis Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 72. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 73. Isis Pharmaceuticals Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Isis Pharmaceuticals Business Overview
Table 75. Isis Pharmaceuticals Recent Developments
Table 76. Sirnaomics Antisense and RNAi Therapeutics Basic Information
Table 77. Sirnaomics Antisense and RNAi Therapeutics Product Overview
Table 78. Sirnaomics Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Sirnaomics Business Overview
Table 80. Sirnaomics Recent Developments
Table 81. Santaris Antisense and RNAi Therapeutics Basic Information
Table 82. Santaris Antisense and RNAi Therapeutics Product Overview
Table 83. Santaris Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Santaris Business Overview
Table 85. Santaris Recent Developments
Table 86. Roche Antisense and RNAi Therapeutics Basic Information
Table 87. Roche Antisense and RNAi Therapeutics Product Overview
Table 88. Roche Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Roche Business Overview
Table 90. Roche Recent Developments
Table 91. Global Antisense and RNAi Therapeutics Sales Forecast by Region (2025-2030) & (Kilotons)
Table 92. Global Antisense and RNAi Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 93. North America Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 94. North America Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 95. Europe Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 96. Europe Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 97. Asia Pacific Antisense and RNAi Therapeutics Sales Forecast by Region (2025-2030) & (Kilotons)
Table 98. Asia Pacific Antisense and RNAi Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 99. South America Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 100. South America Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 101. Middle East and Africa Antisense and RNAi Therapeutics Consumption Forecast by Country (2025-2030) & (Units)
Table 102. Middle East and Africa Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 103. Global Antisense and RNAi Therapeutics Sales Forecast by Type (2025-2030) & (Kilotons)
Table 104. Global Antisense and RNAi Therapeutics Market Size Forecast by Type (2025-2030) & (M USD)
Table 105. Global Antisense and RNAi Therapeutics Price Forecast by Type (2025-2030) & (USD/Ton)
Table 106. Global Antisense and RNAi Therapeutics Sales (Kilotons) Forecast by Application (2025-2030)
Table 107. Global Antisense and RNAi Therapeutics Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Antisense and RNAi Therapeutics Market Size Comparison by Region (M USD)
Table 5. Global Antisense and RNAi Therapeutics Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Antisense and RNAi Therapeutics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Antisense and RNAi Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Antisense and RNAi Therapeutics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2022)
Table 10. Global Market Antisense and RNAi Therapeutics Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Antisense and RNAi Therapeutics Sales Sites and Area Served
Table 12. Manufacturers Antisense and RNAi Therapeutics Product Type
Table 13. Global Antisense and RNAi Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Antisense and RNAi Therapeutics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Antisense and RNAi Therapeutics Market Challenges
Table 22. Global Antisense and RNAi Therapeutics Sales by Type (Kilotons)
Table 23. Global Antisense and RNAi Therapeutics Market Size by Type (M USD)
Table 24. Global Antisense and RNAi Therapeutics Sales (Kilotons) by Type (2019-2024)
Table 25. Global Antisense and RNAi Therapeutics Sales Market Share by Type (2019-2024)
Table 26. Global Antisense and RNAi Therapeutics Market Size (M USD) by Type (2019-2024)
Table 27. Global Antisense and RNAi Therapeutics Market Size Share by Type (2019-2024)
Table 28. Global Antisense and RNAi Therapeutics Price (USD/Ton) by Type (2019-2024)
Table 29. Global Antisense and RNAi Therapeutics Sales (Kilotons) by Application
Table 30. Global Antisense and RNAi Therapeutics Market Size by Application
Table 31. Global Antisense and RNAi Therapeutics Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Antisense and RNAi Therapeutics Sales Market Share by Application (2019-2024)
Table 33. Global Antisense and RNAi Therapeutics Sales by Application (2019-2024) & (M USD)
Table 34. Global Antisense and RNAi Therapeutics Market Share by Application (2019-2024)
Table 35. Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
Table 36. Global Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Antisense and RNAi Therapeutics Sales Market Share by Region (2019-2024)
Table 38. North America Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Antisense and RNAi Therapeutics Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Antisense and RNAi Therapeutics Sales by Region (2019-2024) & (Kilotons)
Table 43. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 44. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 45. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Tekmira Pharmaceuticals Business Overview
Table 47. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 48. Tekmira Pharmaceuticals Recent Developments
Table 49. Arbutus Biopharma Antisense and RNAi Therapeutics Basic Information
Table 50. Arbutus Biopharma Antisense and RNAi Therapeutics Product Overview
Table 51. Arbutus Biopharma Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Arbutus Biopharma Business Overview
Table 53. Arbutus Biopharma Antisense and RNAi Therapeutics SWOT Analysis
Table 54. Arbutus Biopharma Recent Developments
Table 55. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 56. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 57. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 59. Alnylam Pharmaceuticals Business Overview
Table 60. Alnylam Pharmaceuticals Recent Developments
Table 61. Antisense Therapeutics Antisense and RNAi Therapeutics Basic Information
Table 62. Antisense Therapeutics Antisense and RNAi Therapeutics Product Overview
Table 63. Antisense Therapeutics Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Antisense Therapeutics Business Overview
Table 65. Antisense Therapeutics Recent Developments
Table 66. Silence Therapeutics Antisense and RNAi Therapeutics Basic Information
Table 67. Silence Therapeutics Antisense and RNAi Therapeutics Product Overview
Table 68. Silence Therapeutics Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Silence Therapeutics Business Overview
Table 70. Silence Therapeutics Recent Developments
Table 71. Isis Pharmaceuticals Antisense and RNAi Therapeutics Basic Information
Table 72. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Overview
Table 73. Isis Pharmaceuticals Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Isis Pharmaceuticals Business Overview
Table 75. Isis Pharmaceuticals Recent Developments
Table 76. Sirnaomics Antisense and RNAi Therapeutics Basic Information
Table 77. Sirnaomics Antisense and RNAi Therapeutics Product Overview
Table 78. Sirnaomics Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Sirnaomics Business Overview
Table 80. Sirnaomics Recent Developments
Table 81. Santaris Antisense and RNAi Therapeutics Basic Information
Table 82. Santaris Antisense and RNAi Therapeutics Product Overview
Table 83. Santaris Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Santaris Business Overview
Table 85. Santaris Recent Developments
Table 86. Roche Antisense and RNAi Therapeutics Basic Information
Table 87. Roche Antisense and RNAi Therapeutics Product Overview
Table 88. Roche Antisense and RNAi Therapeutics Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Roche Business Overview
Table 90. Roche Recent Developments
Table 91. Global Antisense and RNAi Therapeutics Sales Forecast by Region (2025-2030) & (Kilotons)
Table 92. Global Antisense and RNAi Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 93. North America Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 94. North America Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 95. Europe Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 96. Europe Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 97. Asia Pacific Antisense and RNAi Therapeutics Sales Forecast by Region (2025-2030) & (Kilotons)
Table 98. Asia Pacific Antisense and RNAi Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 99. South America Antisense and RNAi Therapeutics Sales Forecast by Country (2025-2030) & (Kilotons)
Table 100. South America Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 101. Middle East and Africa Antisense and RNAi Therapeutics Consumption Forecast by Country (2025-2030) & (Units)
Table 102. Middle East and Africa Antisense and RNAi Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 103. Global Antisense and RNAi Therapeutics Sales Forecast by Type (2025-2030) & (Kilotons)
Table 104. Global Antisense and RNAi Therapeutics Market Size Forecast by Type (2025-2030) & (M USD)
Table 105. Global Antisense and RNAi Therapeutics Price Forecast by Type (2025-2030) & (USD/Ton)
Table 106. Global Antisense and RNAi Therapeutics Sales (Kilotons) Forecast by Application (2025-2030)
Table 107. Global Antisense and RNAi Therapeutics Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Antisense and RNAi Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Antisense and RNAi Therapeutics Market Size (M USD), 2019-2030
Figure 5. Global Antisense and RNAi Therapeutics Market Size (M USD) (2019-2030)
Figure 6. Global Antisense and RNAi Therapeutics Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Antisense and RNAi Therapeutics Market Size by Country (M USD)
Figure 11. Antisense and RNAi Therapeutics Sales Share by Manufacturers in 2023
Figure 12. Global Antisense and RNAi Therapeutics Revenue Share by Manufacturers in 2023
Figure 13. Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Antisense and RNAi Therapeutics Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Antisense and RNAi Therapeutics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Antisense and RNAi Therapeutics Market Share by Type
Figure 18. Sales Market Share of Antisense and RNAi Therapeutics by Type (2019-2024)
Figure 19. Sales Market Share of Antisense and RNAi Therapeutics by Type in 2023
Figure 20. Market Size Share of Antisense and RNAi Therapeutics by Type (2019-2024)
Figure 21. Market Size Market Share of Antisense and RNAi Therapeutics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Antisense and RNAi Therapeutics Market Share by Application
Figure 24. Global Antisense and RNAi Therapeutics Sales Market Share by Application (2019-2024)
Figure 25. Global Antisense and RNAi Therapeutics Sales Market Share by Application in 2023
Figure 26. Global Antisense and RNAi Therapeutics Market Share by Application (2019-2024)
Figure 27. Global Antisense and RNAi Therapeutics Market Share by Application in 2023
Figure 28. Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Antisense and RNAi Therapeutics Sales Market Share by Region (2019-2024)
Figure 30. North America Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 32. U.S. Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Antisense and RNAi Therapeutics Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Antisense and RNAi Therapeutics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 37. Germany Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Antisense and RNAi Therapeutics Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Antisense and RNAi Therapeutics Sales Market Share by Region in 2023
Figure 44. China Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Antisense and RNAi Therapeutics Sales and Growth Rate (Kilotons)
Figure 50. South America Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 51. Brazil Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Antisense and RNAi Therapeutics Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Antisense and RNAi Therapeutics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Antisense and RNAi Therapeutics Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Antisense and RNAi Therapeutics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Antisense and RNAi Therapeutics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Antisense and RNAi Therapeutics Market Share Forecast by Type (2025-2030)
Figure 65. Global Antisense and RNAi Therapeutics Sales Forecast by Application (2025-2030)
Figure 66. Global Antisense and RNAi Therapeutics Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Antisense and RNAi Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Antisense and RNAi Therapeutics Market Size (M USD), 2019-2030
Figure 5. Global Antisense and RNAi Therapeutics Market Size (M USD) (2019-2030)
Figure 6. Global Antisense and RNAi Therapeutics Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Antisense and RNAi Therapeutics Market Size by Country (M USD)
Figure 11. Antisense and RNAi Therapeutics Sales Share by Manufacturers in 2023
Figure 12. Global Antisense and RNAi Therapeutics Revenue Share by Manufacturers in 2023
Figure 13. Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Antisense and RNAi Therapeutics Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Antisense and RNAi Therapeutics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Antisense and RNAi Therapeutics Market Share by Type
Figure 18. Sales Market Share of Antisense and RNAi Therapeutics by Type (2019-2024)
Figure 19. Sales Market Share of Antisense and RNAi Therapeutics by Type in 2023
Figure 20. Market Size Share of Antisense and RNAi Therapeutics by Type (2019-2024)
Figure 21. Market Size Market Share of Antisense and RNAi Therapeutics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Antisense and RNAi Therapeutics Market Share by Application
Figure 24. Global Antisense and RNAi Therapeutics Sales Market Share by Application (2019-2024)
Figure 25. Global Antisense and RNAi Therapeutics Sales Market Share by Application in 2023
Figure 26. Global Antisense and RNAi Therapeutics Market Share by Application (2019-2024)
Figure 27. Global Antisense and RNAi Therapeutics Market Share by Application in 2023
Figure 28. Global Antisense and RNAi Therapeutics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Antisense and RNAi Therapeutics Sales Market Share by Region (2019-2024)
Figure 30. North America Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 32. U.S. Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Antisense and RNAi Therapeutics Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Antisense and RNAi Therapeutics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 37. Germany Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Antisense and RNAi Therapeutics Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Antisense and RNAi Therapeutics Sales Market Share by Region in 2023
Figure 44. China Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Antisense and RNAi Therapeutics Sales and Growth Rate (Kilotons)
Figure 50. South America Antisense and RNAi Therapeutics Sales Market Share by Country in 2023
Figure 51. Brazil Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Antisense and RNAi Therapeutics Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Antisense and RNAi Therapeutics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Antisense and RNAi Therapeutics Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Antisense and RNAi Therapeutics Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Antisense and RNAi Therapeutics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Antisense and RNAi Therapeutics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Antisense and RNAi Therapeutics Market Share Forecast by Type (2025-2030)
Figure 65. Global Antisense and RNAi Therapeutics Sales Forecast by Application (2025-2030)
Figure 66. Global Antisense and RNAi Therapeutics Market Share Forecast by Application (2025-2030)
